Background
To date, concurrent splenectomy or distal pancreatectomy has been performed in selected cases with advanced gastric cancer to secure the clearance of potential nodal involvement at the splenic hilum or along the splenic artery. However, several recent retrospective studies have reported negative outcomes in prophylactic splenectomy and there have been discussions on the necessity of splenectomy for advanced gastric cancer [
1‐
4].
For patients with advanced gastric cancer not involving the greater curvature of the stomach, a prospective study conducted by the Japan Clinical Oncology Group (JCOG0110) has confirmed that concurrent splenectomy has no oncological advantage despite the increased morbidity [
5], and prophylactic splenectomy is currently not recommended for such cases in the Japanese Gastric Cancer Treatment Guidelines [
6]. However, for advanced gastric cancer involving the greater curvature, concurrent splenectomy remains a standard procedure despite that no solid evidence has been available. Therefore, this study sought to clarify the prognostic impact of splenectomy for patients with proximal advanced gastric cancer involving the greater curvature of the stomach.
Methods
Study population
Initial cohort included 1309 patients who underwent total or subtotal gastrectomy for advanced proximal gastric carcinoma invading greater curvature at the Department of Gastroenterological Surgery, Toranomon Hospital, between January 1975 and December 2015. Among these, 108 patients were selected according to the following inclusion criteria: histopathologically proven adenocarcinoma, T2-4 in the upper 1/3 of the stomach invading the greater curvature, no gross nodal metastasis at the splenic hilum or along the splenic artery, no invasion to the spleen or the pancreas, and no evidence of distant metastases or peritoneal dissemination (both in macroscopic observation and peritoneal lavage). The definition of clinical lymph node-positive was enlarged lymph node (≧8 mm in the minor axis or ≧10 mm in the major axis) by contrast-enhanced abdominal computed tomography. The JCOG 0110 excluded Borrmann type 4 because of their aggressive malignant behavior. On the other hand, we included Borrmann type 4 because this type is thought to be associated with higher rate of peritoneal dissemination due to aggressive invasion of cancer cells to the gastric wall and it is a very important point that we should resect or preserve the spleen for these patients who had type 4 tumor. In the past report, a type 5 gastric cancer contained various types of tumors, from low-grade tumor to a high-grade tumor. However, the type 5 tumor generally has a large tumor diameter, high lymph node metastasis rate, and deeply invasive tumor. And also, these tumors has high rate of vascular invasion and high histological malignancy grade; therefore, Borrmann type 5 tumors were grouped with Borrmann types 3 and 4 [
7,
8].
Then, the 108 patients were divided into two groups according to the concurrent splenectomy: the splenectomy group (n = 63) and spleen preservation group (n = 45), and clinical outcomes were compared.
Surgery
D2 lymphadenectomy was routinely performed with total or subtotal gastrectomy for each patient. In the splenectomy group, lymphadenectomy along the splenic artery (No.11p and 11d lymph nodes) was completely performed with mobilizing the tail of the pancreas and only the spleen was excised while preserving the pancreatic parenchyma. In the spleen preservation group, No.11p and 11d lymph nodes were dissected without mobilizing the pancreatic tail and spleen. Lymph nodes at the splenic hilum (No.10 lymph nodes) were left untouched, but were dissected if judged easily removable in lean patients. In our hospital, treatment of advanced proximal gastric cancer was total gastrectomy with simultaneous splenectomy for adequate regional lymphadenectomy, especially splenic hilar lymph nodes. However, these indications were not established and so the surgeons finally determined whether it should be performed with or without splenectomy.
Clinical stage was determined according to the Union for International Cancer Control TNM Classification of Malignant Tumors, 7th edition on pathological examination [
9]. A diagnosis of postoperative complications was made when we observed adverse events that corresponded to grade 2 or greater in the Clavien-Dindo classification [
10].
Data analyses
Pairwise differences of proportions and medians were analyzed by the chi-squared test, Fisher’s exact test, or Mann-Whitney U test, as appropiate. Cumulative overall survival rates (OS) and recurrence-free survival rates (RFS) were analyzed by the Kaplan-Meier method. All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) version 19.0J for Windows (SPSS Inc., Chicago, IL). This study was approved by the Internal Review Board of Toranomon Hospital.
Discussion
Concurrent splenectomy is rarely performed in Western countries because it is reportedly associated with increased risk of postoperative complications with no survival benefits [
11,
12]. The JCOG 0110 study, a prospective randomized comparative study conducted in Japan, reported that prophylactic splenectomy has no prognostic advantage in patients with proximal advanced gastric cancer not invading the greater curvature of the stomach [
5]. However, it remains inconclusive whether splenectomy is needed or not in patients with proximal advanced gastric cancer involving the greater curvature of the stomach, which would be a risk factor for nodal involvement around the splenic hilum. The current study focused on the specific population with proximal gastric cancer involving the greater curvature of the stomach and revealed that splenectomy was associated with increased risk of morbidity, and no prognostic advantage except for the specific subpopulation with Bormann type 1 or 2 tumor.
From the standpoint of safety of surgery, concurrent splenectomy was associated with significant increase in blood loss and postoperative complications in this study. The overall rate of postoperative morbidity was similar with those in the prospective JCOG0110, and the current study clarified that splenectomy was associated with significantly higher rate of pancreas-related complications (
p = 0.003) such as pancreatic fistula/abdominal abscess [
13,
14]. Mobilization of the pancreas from the retroperitoneum and extensive lymphadenectomy along the splenic vessels may be associated with these clinical results in the splenectomy group [
15,
16]. Given that the rate of nodal involvement in the dissected lymph nodes was only 6%, oncological relevance of the extensive lymphadenectomy is questionable and the current results may support the avoidance of prophylactic splenectomy even in the cases with proximal advanced gastric cancer located at the greater curvature of the stomach.
In previous retrospective studies, regardless of tumor location, the rates of 5-year survival were ≥10% lower in the splenectomy group than those in the spleen preservation group [
4,
17‐
19]. In the present study, however, no significant prognostic difference was confirmed between the splenectomy group and the spleen-preserving group in both 5-year RFS (60.2 vs. 67.3%) and 5-year survival rates (63.7 vs. 73.6%). Recurrence after spleen-preserving surgery in the corresponding lymph nodes which will be excised when splenectomy is performed was observed only in two (4.4%) patients. Furthermore, the patterns of recurrence were similar regardless of the splenectomy, with relatively high proportion of peritoneal dissemination (70–80%) among all recurrent sites in the study group. These results may also support that prophylactic splenectomy is unnecessary for most of the cases with proximal advanced gastric cancer.
Of note, however, subset analysis stratified by the macroscopic subtype of gastric cancer showed different tendencies of prognostic advantage in splenectomy between Borrmann type 1 or 2 and Bormann type 3, 4, or 5. The latter subtypes of gastric cancer is thought to be associated with higher rate of peritoneal dissemination due to aggressive invasion of cancer cells to the gastric wall, and as expected, there was no prognostic advantage of splenectomy due to high rate of peritoneal recurrence [
20]. Meanwhile, Borrmann type 1 or 2 is mass-forming subtypes with less aggressive invasion of cancer cells into the stomach wall. The subanalysis showed that the splenectomy group for Borrmann type 1 or 2 may be associated with marginal prognostic advantage (Hazard ratio, 1.98; 95% CI, 0.94–4.20;
p = 0.072). Actually, the two patients who had initial recurrence in the lymph node at the splenic hilum had Bormann type 1 or 2 tumor with no evidence of peritoneal dissemination.
From the practical standpoint, the current results suggest that prognostic advantage of splenectomy is relatively small in the overall population with proximal advanced gastric cancer due to aggressive patterns of recurrence including peritoneal dissemination. However, the subanalysis suggested a potentially encouraging result in a specific subpopulation with Borrmann type 1 or 2 tumors. Given that 35% of the patients with definitive findings of mesenteric infiltration or nodal metastasis at the splenic hilum or along the splenic artery (the reference cohort in this study) achieved median recurrence-free survival of 140.9 months after therapeutic lymphadenectomy; splenectomy with extensive lymphadenectomy may be effective for selected population with locally advanced cancer involving the lymph nodes. Therefore, prophylactic splenectomy with extensive lymphadenectomy remains a potentially favorable surgical approach for patients with Borrmann type 1 or 2.
The limitation of this study includes its retrospective nature and selected population. However, perioperative management was similar during the study period, and the current study is based on a prospectively collected database for consecutive patients. Although prophylactic splenectomy showed no significant prognostic advantage in the overall population, the subpopulation with Borrmann type 1 or 2 might remain a candidate for splenectomy with marginal improvement of overall survival after splenectomy with relatively low rate of peritoneal recurrence. An external validation study using a sufficient number of patients would be needed to confirm the current observations.
Conclusions
Prophylactic splenectomy in advanced proximal gastric cancer invading the greater curvature increases postoperative complications without clearly improving RFS or OS, indicating that the procedure is not effective from a viewpoint of risk-benefit balance. However, in a subgroup of patients with less invasive macroscopic subtypes of gastric cancer, splenectomy might have a potential advantage for local control of tumor and further investigation is needed.